National Comprehensive Cancer Network

About NCCN

NCCN Qualifies First Community Sites for Affiliate Research Project

The NCCN Affiliate Research Project (ARP), developed by the NCCN Oncology Research Program (ORP), has qualified its first seven affiliate sites from the Fox Chase Cancer Center Partners Program, the Seattle Cancer Care Alliance Affiliate Network, and University of Alabama at Birmingham Cancer Care Network. The newly qualified ARP community sites are:

Fox Chase Cancer Center

  • Virtua, under the direction of Principal Investigator (PI) Michael Entmacher, MD, includes Hematology Oncology Associates of South Jersey, Mt. Holly, NJ, and Comprehensive Cancer and Hematology Specialists, Voorhees, NJ
  • AtlantiCare Cancer Care Institute, under the direction of PIs Michael J. Kane, MP, FACP, and James C. Wurzer, MD, PhD, Egg Harbor Township, NJ
  • South Jersey Healthcare, under the direction of PI Kush Sachdeva, MD, includes Southern Oncology-Hematology Associates, P.A., Vineland, NJ, South Jersey Radiation Oncology, P.C., Vineland, NJ and The Minniti Center- Medical Oncology & Hematology, Mickleton, NJ

Seattle Cancer Care Alliance

  • Bozeman Deaconess Hospital, under the direction of PI Jack Hensold, MD, includes Bozeman Deaconess Cancer Center, Bozeman, MT
  • MultiCare Health System, under the direction of PI John A. Keech, Jr., DO, FACOI, includes MultiCare Regional Cancer Center, Tacoma, WA
  • Wenatchee Valley Medical Center, under the direction of PI Mitchell Garrison, MD, includes Wenatchee Valley Cancer Treatment Center, Wenatchee, WA

University of Alabama at Birmingham Cancer Care Network

  • Medical Center of Central Georgia, under the direction of PI Frederick Schnell, MD, includes Central Georgia Cancer Care, P.C., Central Georgia Gynecologic Oncology, and Central Georgia Radiation Oncology Center, Macon, GA

The mission of the NCCN ARP is to improve patient outcomes and to advance medical science through clinical research conducted through collaboration among the National Comprehensive Cancer Network® (NCCN®), the 21 NCCN Member Institutions, and their community-based affiliate networks. The NCCN ARP plans to approve a minimum of three additional sites this year to potentially support more than 50 actively enrolling ORP trials.

The NCCN ORP is organized to obtain funding to support scientifically meritorious research projects at NCCN Member Institutions. Policies and standards for the program were set by the NCCN Investigator Steering Committee, a group comprised of senior research physicians appointed by each NCCN Member Institution. To date, the NCCN ORP has received more than $36 million in research grants from pharmaceutical and biotech companies to support investigator-initiated trials including, but not limited to, evaluation of innovative regimens, mechanism of action, and exploration of extended uses for specific agents.

Affiliate sites of the ORP will have access to new and innovative cancer drugs for their patients in collaboration with NCCN Member Institutions, and Principal Investigators of NCCN-funded studies will have access to NCCN-qualified community sites. "We are delighted with the addition of community affiliates. The qualification of these sites will not only enhance studies through the diversification of patient cohorts, but also expedite accrual so that important research questions can be answered in a timely manner," said Diane Paul, MS, RN, Vice President of the Oncology Research Program.